Abstract
Cerebrovascular diseases are known as serious public health problem worldwide, which can be addressed more precisely through molecular imaging of non-functional brain cells. CDP-choline is an active cerebrovascular chemotherapeutic agent that can be used for diagnosis of cerebrovascular diseases post radiolabeling with gamma-emitter radioisotopes. In this study we developed Tc-99m labeled CDP-choline for imaging of cerebrovascular diseases particularly alzheimer, stroke, and parkinson's diseases. The radiosynthesis reaction resulted 97.47 +/- 2.34% radiochemical with promising stability, that is, >95% up to 6 h in blood serum. The biodistribution study in healthy mice revealed non-accumulated uptake of radiochemical in key body organs; in brain it was 8.59 +/- 1.11% ID/g at 1h post-injection which washed-out leaving behind 0.87 +/- 0.61% ID/g at 24 h post-injection. The over-all data revealed the Tc-99m-CDP-choline could be a good candidate for further imaging investigations in diseased animal model.